GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Aerocrine AB (FRA:A0C) » Definitions » Cash Flow from Investing

Aerocrine AB (FRA:A0C) Cash Flow from Investing : €-0.34 Mil (TTM As of Mar. 2015)


View and export this data going back to . Start your Free Trial

What is Aerocrine AB Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Mar. 2015, Aerocrine AB spent €0.00 Mil on purchasing property, plant, equipment. It gained €0.00 Mil from selling property, plant, and equipment. It spent €0.00 Mil on purchasing business. It gained €0.00 Mil from selling business. It spent €0.00 Mil on purchasing investments. It gained €0.00 Mil from selling investments. It paid €0.00Mil for net Intangibles purchase and sale. And it paid €0.00 Mil for other investing activities. In all, Aerocrine AB spent €0.08 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Mar. 2015.


Aerocrine AB Cash Flow from Investing Historical Data

The historical data trend for Aerocrine AB's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aerocrine AB Cash Flow from Investing Chart

Aerocrine AB Annual Data
Trend Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14
Cash Flow from Investing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -6.25 -0.71 -0.67 -0.40 -0.38

Aerocrine AB Quarterly Data
Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.14 -0.09 -0.11 -0.06 -0.08

Aerocrine AB Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

Aerocrine AB's Cash Flow from Investing for the fiscal year that ended in Dec. 2014 is calculated as:

Aerocrine AB's Cash Flow from Investing for the quarter that ended in Mar. 2015 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2015 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.34 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aerocrine AB  (FRA:A0C) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

Aerocrine AB's purchase of property, plant, equipment for the three months ended in Mar. 2015 was €0.00 Mil. It means Aerocrine AB spent €0.00 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

Aerocrine AB's sale of property, plant, equipment for the three months ended in Mar. 2015 was €0.00 Mil. It means Aerocrine AB gained €0.00 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

Aerocrine AB's purchase of business for the three months ended in Mar. 2015 was €0.00 Mil. It means Aerocrine AB spent €0.00 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

Aerocrine AB's sale of business for the three months ended in Mar. 2015 was €0.00 Mil. It means Aerocrine AB gained €0.00 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

Aerocrine AB's purchase of investment for the three months ended in Mar. 2015 was €0.00 Mil. It means Aerocrine AB spent {stock_data.stock.currency_symbol}}0.00 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

Aerocrine AB's sale of investment for the three months ended in Mar. 2015 was €0.00 Mil. It means Aerocrine AB gained €0.00 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Aerocrine AB's net Intangibles purchase and sale for the three months ended in Mar. 2015 was €0.00 Mil. It means Aerocrine AB paid €0.00 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Aerocrine AB's cash from discontinued investing activities for the three months ended in Mar. 2015 was 0.00 Mil. It means Aerocrine AB paid €0.00 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

Aerocrine AB's cash from other investing activities for the three months ended in Mar. 2015 was €0.00 Mil. It means Aerocrine AB paid €0.00 Mil for other investing activities.


Aerocrine AB Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of Aerocrine AB's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


Aerocrine AB (FRA:A0C) Business Description

Traded in Other Exchanges
N/A
Address
Aerocrine AB is a medical technology company focused on improving the treatment of patients with inflamed airways. The company offers exhaled nitric oxide (NO) monitoring devices for research and clinical applications. Aerocrine's devices utilize methods for measuring minute concentrations of NO, and incorporate NO scrubbers to eliminate atmospheric NO from the patient's breath. Measuring NO values helps doctors differentiate asthma from similar conditions, and differentiate various forms of asthma from other airway diseases. The company markets two products globally namely NIOX Flex and NIOX MINO. These products are widely used by primary care asthma specialists in Europe, and have recently gained US regulatory approval. Distribution agreements have also been signed in Japan, and regulatory approval has been secured in China. The company has offices and subsidiaries in Sweden, Germany, the United States, and the United Kingdom. The parent company is located in Solna, Sweden, and has sales enterprises in Sweden, Germany, the United States, and the United Kingdom. NIOX was replaced by its successor, NIOX FLEX in 2007. NIOX FLEX was the first tailor-made device for measuring exhaled nitric oxide (NO). NIOX FLEX includes enhanced data handling facilities, add-on research kits, and USB ports for communication. Moreover, a new application, NIOX Flex Flow, can determine whether lung inflammation is located centrally or more peripherally, which can be highly significant to therapy choices. The Nasal Research Kit allows measurement of nasal NO, while the FlexFlo Research Kit enables measurement of exhaled NO at variable flow rates, to help identify the location of inflammation. NIOX MINO is a compact hand-held device, marketed for smaller clinics, healthcare centers, and hospitals. NIOX MINO is intended for routine measurements of NO. Patients hold the NIOX MINO and breathe into the mouthpiece. An audible tone helps patient maintain the right flow during exhalation, whereupon results are displayed on the front of the device.

Aerocrine AB (FRA:A0C) Headlines

No Headlines